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Capsule: 
The new automated AMH assays provide values that are substantially lower than existing 
AMH ELISAs. Assay specific interpretation is necessary with international standardization 
urgently required.
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ABSTRACT  
 
Objective: To compare anti-Müllerian hormone (AMH) assay performance characteristics 
from the new automated Roche and Beckman Coulter assays with the existing Beckman 
Coulter Gen II and Ansh Labs assays. 
Design: Prospective assay evaluation. 
Setting: An university affiliated clinical chemistry laboratory. 
Patient(s): Randomly sampled patients (n=83) referred for serum AMH at Invicta 
Laboratories prior to commencement of IVF cycle between September and October 2014. 
Laboratory and clinical investigators were blind to biochemical and outcomes respectively.  
Interventions: None. 
Main Outcome Measure(s): Serum AMH concentration. 
Results(s): Intra-assay coefficients of variation were low; Ansh≤9.0%, Gen II≤5.8%, 
Access≤10.7%and Elecsys≤2.8%. The Passing–Bablok regression equations (in pmol/l) was 
y (Access) =0.128+(0.781×Gen II) and y (Access) =  0.302+(0.742xAnsh). For y (Elecys) = 
0.087+(0.729xGen II) and y (Elecys) = 0.253+(0.688xAnsh). For y (Elecys) = 0.943-
(0.037xAccess). All four assays AMH exhibited moderate positive correlation with AFC (r 
0.62-0.64), number of cumulus oocyte complexes (r=0.60-0.64) and MII oocytes (r=0.48-
0.50). Prediction of pregnancy as determined by area under the receiver operator 
characteristic curve was uniformly low for all assays (AUROC=0.62-0.63). 
Conclusions: The novel automated assays exhibit strong concordance in calibration but 
derived values are substantially lower than obtained from preexisting assays with assay 
specific interpretation required for routine clinical use. These results highlight the need for an 
international AMH standard. 
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Introduction 
Anti-Müllerian hormone (AMH) has rapidly established countenance as the ovarian 
biomarker of choice in reproductive medicine(1-4). With recognition of its clinical utility 
beyond simple ovarian response prediction(3, 5, 6), there has rapid development of several 
AMH assays(1). At present two ELISA AMH assays dominate the clinical arena; the 
modified Beckman Coulter Generation II assay and the Ansh Labs AMH assay(7-9). These 
ELISA assays are inevitably limited by their technical characteristics that limit their up 
scaling for routine clinical chemistry laboratories. Furthermore the Beckman Coulter 
Generation II assay exhibited complement interference in fresh samples requiring a modified 
protocol to be developed, introducing a further step that would complicate robotic 
instrumentation(10, 11).  
 
Given the potential wide spread application of AMH measurement in several clinical spheres 
an accurate, robust, and automated assay was urgently required(12). Two such assays have 
now been developed and released by Beckman Coulter and by Roche Diagnostics on their 
Access and Elecsys platforms respectively(13). Although these two companies are 
intrinsically linked due to the use of identical antibodies in their respective automated AMH 
assays, assay development differed(13). Consequently Roche noted that their assay provided 
values which were substantially lower than the two pre-existing ELISA assays(13). In contrast 
documentation from Beckman Coulter suggests equivalent values of the Access AMH assay 
to those reported by the AMH Gen II ELISA. To date we are unaware of any external 
validation of the performance of these two new automated AMH assays (Beckman Coulter 
Access AMH assay and the Roche Diagnostics Elecsys AMH assay) relative each other and to 
the two current clinical standard assays (Beckman Coulter Generation II ELISA and the Ansh 
Labs ultrasensitive AMH/MIS ELISA).The importance of such post-marketing external 
validation has previously been highlighted by the release of field safety notices by Beckman 
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Coulter, when laboratories observed discordance between anticipated and actual results(8, 14, 
15). To address this urgent need for external validation we have used a pragmatic design and 
compared the performance of all four AMH assays utilizing patients referred for assisted 
conception. 
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Material and methods 
Serum AMH was measured in 83 randomly selected women undergoing a standard IVF cycle 
between September 2014 and October 2014(16). All samples were collected on cycle day 2-5, 
frozen at -80°C with AMH analysis performed on the same day for all four assays in 
accordance with manufacturers protocols after a single freeze thaw. The AMH assays used 
were: the Beckman Coulter modified Generation II AMH assay, Ansh Labs ultrasensitive 
AMH assay, Roche Diagnostics Elecsys AMH assay and Beckman Coulter Access AMH 
assay. For all assay systems we have presented results in ng/ml. Serum samples with results 
above the upper measuring range for each method were diluted automatically (using the 
reagents supplied by the manufacturers of the assays) and analyzed again. Manufacturer 
reported assay characteristics, measuring ranges, analytical sensitivity and detection limits are 
provided in Supplemental Material Table 1. 
 
In the first stage of the study, the precision of the AMH tests was evaluated for two different 
control serum as supplied by the manufacturers (Controls 1 and 2 for Beckman Coulter Gen 
II, Controls 1 and 2 for Ansh Labs, PreciControl AMH 1 and 2 for Roche Elecsys and 
Controls 1, 2 and 3 for Beckman Coulter Access) in accordance with the Clinical and 
Laboratory Standards Institute protocol (CLSI). In the assessment of the accuracy of the 
results, we used the degree of agreement between the average value obtained from the series 
of control tests, and the predicted value for a particular control material level declared by the 
manufacturer(17). 
 
Statistical analyses were performed using Stata version 13 and MedCalc 11.6.1.0. AMH 
values were log transformed to approximate normal distributions. Assay type was tested by 
generalized linear regression or paired t-test. Passing-Bablok regression equations were used 
to estimate the relationship between the results obtained with different analyses. Bland-
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Altman plots were used to compare tests graphically to assess bias and check whether the 
variability in measures was homoscedastic. Correlations among the number of antral follicles 
(AFC), number of acquired cumuluses, MII, biochemical pregnancy and clinical pregnancy 
were evaluated by the Spearman rank correlation test. Receiver Operating Characteristic 
(ROC) analysis was performed to obtain the sensitivity, specificity and the cut-off value for 
each test. A 95% confidence interval was set as being statistically significant in all tests. 
 
 
Results 
Results of precision and accuracy for each AMH assay are shown in Table I. The obtained 
coefficients of variation (CV) for compared sets of analytical and evaluated AMH values were 
satisfactory. For each assay, the analyzed CV value was less than 11%. For both automated 
methods compared, correctness was satisfactory - in all of the analyzed cases the load did not 
exceed the value of 11%.  
 
Comparative analysis of the four AMH assays was performed on a total of 83 patients with 
baseline and IVF outcome characteristics provided in Supplemental material Table 2. In brief 
women ranged in age from 24-44 years, 1-35 cumulus oocyte complexes were retrieved and 
40/83 (48.2%) achieved a clinical pregnancy. Figure 1 and Supplemental Table 3 
demonstrates that there was no overall difference in distribution of AMH values between the 
four assays (p=0.07). However, although the AnshLabs/Beckman Coulter Gen II values were 
broadly comparable (p=0.87), direct comparison of the other individual assay pairs 
demonstrated significant differences; AnshLabs/Roche Elecsys (p<0.0001), 
AnshLabs/Beckman Coulter Access (p<0.001), Beckman Coulter Gen II/RocheElecsys 
(p<0.0001), Beckman Coulter Gen II/Beckman Coulter Access (p<0.0001) and Roche 
Elecsys/Beckman Coulter Access (p<0.001). 
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Figure 2 presents the Passing-Bablok regressions and Bland-Altman plots comparing pairs of 
assays across the range of AMH values. The Passing-Bablok plots, which depict the linear 
regression line and 95% confidence interval (CI) relative to a slope of 1, show that there was a 
linear relationship between each combination of the four assays, however there was marked 
disparity when comparing some of the assays. In particular the new automated Beckman 
Coulter Access and Roche Elecsys assays gave considerably lower values than the Beckman 
Coulter Gen II assay and the Ansh Labs assay. Supplemental Table 2 provides the regression 
equations and 95% confidence intervals for the slope and intercept. Bland-Altman plots 
present the disparity in AMH values relative to the mean of the two assays to help determine 
systematic error and whether it is uniform across the range of results. The Bland-Altman plots 
show that as mean AMH levels increase, the differences between the two values become 
larger, with the exception of the comparison of the Beckman Coulter Access and Roche 
Elecsys assays where the relationship was constant across the range of AMH values. 
 
In addition to these assay performance characteristics we examined the association of assay 
specific AMH values with the alternative ovarian biomarker antral follicle count (AFC) and 
clinicaloutcomes. For all four assays AMH exhibited moderate positive correlation with AFC, 
number of cumulus oocyte complexes and MII oocytes (Table 2). With respect to AMH 
prediction of biochemical and clinical pregnancy the area under the ROC curves were 
uniformly low (Supplemental Figure 1). 
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Discussion 
Recognition of the clinical utility of AMH has led to its rapid adoption by many assisted 
conception clinical laboratories. Despite consistent evidence that AMH can predict ovarian 
response(16, 17), individual clinicians have had their confidence shaken due to issues with 
sample handling, complement interference, non-standardized reporting and lack of 
reproducibility(1, 18). Herein we report that the new automated assays from Beckman Coulter 
and Roche Diagnostics assay exhibit appropriate technical characteristics, but the lack of 
universal calibration means that these values are quite different from the current manual 
assays. Furthermore despite package inserts suggesting similar calibration for the Beckman 
Coulter modified Gen II and their new Access assay, we identify that the new automated 
assay from this manufacturer derives values that are approximately 22% lower than 
anticipated. 
 
In accordance with previous reports we confirm that all four assays exhibit moderate 
correlations with antral follicle count and ovarian response as defined by both number of MII 
oocytes and total oocyte number (4, 19). This confirms that for ovarian response prediction all 
four assays could be potentially used, with the other technical aspects of low coefficients of 
variation and reproducibility driving selection. In keeping with the published literature(20), all 
four assays exhibited weak correlations with biochemical and clinical pregnancy. We were 
unable to examine the association with live birth, but we would anticipate that to be equally 
weak based on the strength of association with clinical pregnancy and previous meta-
analyses(5, 21).  
 
The discordance between the values obtained by the two Beckman Coulter assays is a further 
example of post-marketing surveillance identifying potential issues with assay performance.  
In the package insert of the Access assay the passing-Bablok regression is Access = (0.09 + 
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0.95 x Gen II), suggesting approximately similar values should be obtained between the 
modified Gen II assay and the new Access assay in contrast to the 22% reduction that we 
observe in the current study. In support of our current findings is that the Access and Elecsys 
assay return similar values and the reduction that we observe in the Elecsys assay values 
relative to Gen II and Ansh Labs are in accordance with the original manufacturers 
description of the assay(13). The underlying cause for this discordance is unclear but the 
systematic differences would suggest a difference in calibration rather than assay 
pharmacokinetics or linearity. Elecsys assay standardization was accomplished via sample 
value transfer from the Beckman Coulter AMH Gen II assay, unmodified version using an 
aged serum panel. However the limitations of this approach were acknowledged by 
Roche(13), as it does not overcome the high degree of between-laboratory variability of the 
manual AMH assay, it does not exclude residual complement activity interference in the aged 
reference serum panel and that the modified AMH Gen II assay methodology delivers 
increased AMH concentrations if compared to the unmodified assay or the Elecsys AMH. At 
present the method for Access assay standardization methodology has yet to be reported.  
 
Currently there is no agreed international standard for AMH. This is increasingly important as 
routine uptake is accelerating and assays are readily available from several manufacturers, 
with additional manufacturers developing assays. To date we have used regression equations 
to facilitate pooling of AMH data derived from different sources(22). Standardization of 
reported values would facilitate development of general reference ranges to identify 
individuals or population subgroups, for example, women at risk of ovarian hyperstimulation 
syndrome(17, 23).  The overall cost of diagnostic testing would be reduced, by negating the 
need for repeat testing in a clinician/assay service provider specific manner. Patient safety 
would also be enhanced as large differences in assay calibration may lead to misinterpretation 
of clinical course when different assays are used or clinicians are unaware of assay 
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differences. Given these issues, a human recombinant AMH international standard needs to be 
urgently developed and adopted. 
 
Strengths and limitations of the study require consideration. This study represents a pragmatic 
comparison of AMH measurement methods using an unselected group of patients referred for 
clinical AMH measurement prior to undertaking assisted conception. In our center all patients 
routinely have AMH measured in advance of ovarian stimulation making our results 
generalizable to the assisted conception population. We had data on important clinical 
outcomes, including number of cumulus oocyte complexes, mature oocytes retrieved and 
clinical pregnancies. That we observe equivalent correlations and predictive capacity similar 
to those previously reported from much larger series gives confidence in our findings. As we 
suggest, recent clinical problems with the Beckman Coulter Gen II assay suggest the need for 
tighter regulation of this increasingly important biochemistry assay using international 
standards and immunoassays that perform consistently in the long term. Plans for a National 
External Quality Assessment Service scheme in the UK are being developed to achieve this. 
Lot-to-lot variation could not be assessed, and we could not run standards from the different 
assay manufacturers on the others platform due to species specificity of the antibodies.  
 
In conclusion we demonstrate that all four assays can be utilized clinically for ovarian 
response prediction with greatest precision exhibited by the Roche automated AMH assay. 
However, the values generated by these assays can be markedly different and assay specific 
interpretation is required.   
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Table 1.  The results of the precision and accuracy of AMH assays (according to Immunotech: CV admissible–14,2%, B admissible–20%). 
 
Control 
sample 
LOT 
Nominal 
value [ng/ml] 
Range Average [ng/ml] SD CV[%] B[%] 
AnshLabs  
AMH/MIS ELISA 
Control 1 
111813 
1.50 1.11-1.89 1.46 0.13 9.00 -2.5 
Control 2 4.40 3.50-5.30 4.26 0.38 8.80 -3.1 
Beckman Coulter 
AMH Gen II ELISA 
Control 1 
334490 
3.00 2.40-3.60 2.88 0.17 5.82 -4.0 
Control 2 8.80 7.00-10.60 8.17 0.16 1.95 -7.2 
Roche  
Elecsys AMH 
PreciControl 1 177753 0.99 0.78-1.20 0.98 0.03 2.80 -0.9 
PreciControl 2 177754 5.41 4.27-6.55 5.34 0.11 2.00 -1.3 
Beckman Coulter  
Access AMH assay 
Control 1 
489202 
0.86 0.584-1.13 0.86 0.09 10.76 -0.2 
Control 2 4.39 3.41-5.38 4.39 0.32 7.40 0.0 
Control 3 13.17 9.11-17.22 13.16 1.35 10.25 0.0 
 
AMH – Anti-Müllerian Hormone, LOT – batch Lot number, SD – standard deviation, CV - coefficient of variation, B- bias 
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Table 2. The correlation between assay specific AMH levels and antral follicle count, number of cumulus oocyte complexesand number of MII 
oocytes. 
 ELISA assays Automated assays 
 
Ansh Labs 
AMH/MIS ELISA 
Beckman Coulter 
AMH Gen II ELISA 
Roche 
Elecsys AMH 
Beckman Coulter 
AccessAMH assay 
AFC 0.620 0.619 0.636 0.628 
Cumulus oocyte complexes 0.605 0.616 0.644 0.615 
MII oocytes 0.477 0.501 0.502 0.486 
 
All correlation coefficients p<0.0001 
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Figure Legends 
Figure 1: Distribution of values measured by the four AMH assays. 
Individual assay values with median values and interquartile range indicated. 
 
Figure 2: Passing-Bablok regression (A-F) (solid line = regression curve and 95% confidence 
interval (CI) relative to a slope of 1) and Bland-Altman graphs (G-L) (solid line = mean 
difference; dotted lines = 95% CI) were obtained with the four assays. Individual Passing-
Bablok regression equations are provided in Supplemental Table 4. 
 
Supplemental Figure 1: Receiver operating characteristic curves and values (95%CI) for 
prediction of (A) biochemical pregnancy and (B) clinical pregnancy. 
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Supplemental materials: 
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Supplemental Table 1: Anti-Müllerian hormone (AMH) assays characteristics 
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Competitor Assays Beckman Coulter 
AMH Gen II1, 2 
AnshLabs 
Ultrasensitive3 
Roche Assay 
Elecsys® AMH4 
Beckman Coulter  
Access 2 IA AMH5 
Assay type Manual Manual Automated Automated 
Imprecision < 8% < 6% 1.8-2.0% 2.87-4.34 % 
Sample type serum, plasma serum, plasma serum, Li-heparin plasma Serum, Li-heparin plasma 
Minimum sample volume 20 µl 50 µl 50 µl 20 µl 
Incubation time < 3hrs 2.5 hrs 18 min 39 min 
Limit of detection (LoD) 0.08 ng/ml 0.023 ng/ml 0.01 ng/ml d 0.02 ng/ml 
Limit of Quantification (LoQ) 0.16 ng/ml 0.06 ng/ml 0.03 ng/ml d 0.08 ng/ml 
Measurement range 0.16-22.5 ng/ml 0.06-11.6 ng/ml 0.01-23.0 ng/ml 0.02-24.0 ng/ml 
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Supplemental Table 2: Patient characteristics and pregnancy outcomes of study group 
 
 median 95% CI min-max 
Number of patients/cycles 83 
Age of women (years) 33 32-34 24-44 
Antral follicle count (AFC) 12 9-13 1-35 
Number of acquired cumuluses 11 8-13 1-35 
Number of MII 6 6-7 0-26 
Number of embryos transferred 1 1-1 0-2 
Clinical pregnancy rate per cycle started (n, %) 40/83 (48.2%) 
Biochemical pregnancy rate per cycle started (n, %) 48/83 (57.8%) 
Ectopic pregnancy rate per cycle started (n, %) 0/83 (0%) 
Miscarriage rate per cycle started (n, %) 2/83 (2.4%) 
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Supplemental Table 3: Summary characteristics of AMH measurements for all four assays. 
 ELISA assays Automated assays 
 
Ansh Labs 
AMH/MIS ELISA 
Beckman Coulter 
AMH Gen II ELISA 
 Beckman Coulter 
AccessAMH assay 
Roche 
Elecsys AMH 
Median [ng/ml] 3.34 3.21 2.83 2.44 
95% CI 2.054 – 4.390 2.253 – 4.344 1.896 – 3.609 1.782 – 3.010 
Minimum 0.02 0.02 0.07 0.06 
Maximum 22.06 22.00 13.82 13.62 
25 - 75 P 1.330 – 5.842 1.372 – 5.642 1.193 – 4.755 1.140 – 4.202 
 
 
 24 
Supplemental Table 4: Passing-Bablok regression equations comparing assay values 
 
Passing-Bablok Regression equations where y=slope(x) + intercept, where y is represented in vertical column and x horizontal columns 
Slope and Intercept are provided with 95% Confidence Interval (95%CI).
 ELISA assays Automated assays 
 Ansh Labs 
AMH/MIS ELISA 
Beckman Coulter 
AMH Gen II ELISA 
Roche 
Elecsys AMH 
Beckman Coulter 
Access AMH assay 
Ansh Labs 
AMH/MIS ELISA - 
Slope: 1.041 (95%CI 0.994, 1.101) 
Intercept: -0.201 (95%CI -0.327, -0.076) 
Slope: 1.454 (95%CI  1.379, 1.526) 
Intercept: -0.368 (95%CI  -0.507, -0.256) 
Slope: 1.348 (95%CI  1.262, 1.437)x 
Intercept: -0.407 (95%CI  -0.572, -0.234) 
 
Beckman Coulter 
AMH Gen II ELISA 
Slope: 0.960 (0.908, 1.006) 
Intercept: 0.193 (0.076, 0.297) - 
Slope: 1.372 (95%CI 1.327, 1.416) 
Intercept: -0.119 (95%CI -0.018, -0.050) 
Slope: 1.280 (95%CI 1.242, 1.320 ) 
Intercept: -0.164 (95%CI -0.262, -0.086) 
 
Roche 
Elecsys AMH 
Slope: 0.688 (0.656, 0.725) 
Intercept: 0.253 (0.186, 0.333) 
Slope: 0.729 (0.706, 0.754) 
Intercept: 0.087 (0.037, 0.128) - 
Slope: 0.943 (95%CI 0.893, 0.972) 
Intercept: -0.037 (95%CI -0.094, 0.026) 
 
Beckman Coulter 
Access AMH assay 
Slope: 0.742 (95%CI 0.696, 0.792) 
Intercept: 0.302 (95%CI 0.185, 0.398) 
Slope: 0.781 (95%CI 0.758, 0.805) 
Intercept: 0.128 (95%CI 0.070, 0.198) 
Slope: 1.061 (95%CI 1.028, 1.120) 
Intercept: 0.039 (95%CI -0.030, 0.096) 
- 
     
 25 
Supplemental Table 5: Area under the receiver operating characteristic curves (95%CI) for prediction of (A) biochemical pregnancy and (B) clinical 
pregnancy. 
 
 
 
 ELISA assays Automated assays 
 
Ansh Labs 
AMH/MIS ELISA 
Beckman Coulter 
AMH Gen II ELISA 
Roche 
Elecsys AMH 
Beckman Coulter 
Access AMH assay 
Biochemical Pregnancy 0.64 (0.52, 0.77) 0.63 (0.51, 0.77) 0.63 (0.51, 0.76) 0.65 (95CI 0.53, 0.78) 
Clinical pregnancy 0.63 (0.51, 0.75) 0.61 (0.49, 0.73) 0.62 (0.50, 0.74) 0.63 (0.51, 0.76) 
